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INTRODUCTION
Galactosemia may be due to three distinct enzymatic deficiencies which constitute the Leloir pathway of galactose metabolism. Classic galactosemia (CG, OMIM
#230400) is an autosomal recessive disorder caused by deficient activity of galactose-1-phosphate uridyltransferase (GALT), the second enzyme in this pathway and that is
responsible for the interconversion of galactose-1-P to glucose-1-P. CG is the most frequent form of galactosemia; clinically, it presents in the neonatal period, with acute
manifestations following milk intake, and is often fatal during infancy. Galactose restricted diet, the only currently available therapeutic strategy, can prevent or resolve the
acute symptoms, but it is ineffective in preventing long-term complications, even in the cases with early identification and treatment (1, 2).
The non-existence of a long-term effective treatment negatively affects the cost – benefit ratio of galactosemia Newborn Screening (NBS) and it is the main reason
why it is only included in a minority of European NBS programs. In spite of this, a significant number of galactosemia cases are identified in programs not including it, due to
the differential diagnosis of other pathologies. Also in Portugal this has been happening since the beginning of the Phenylketonuria (PKU) screening in 1979.
With this work, we intend to analyze all cases of CG that come to our knowledge since the inclusion of tandem mass spectrometry technology in the Portuguese NBS
laboratory, trying to understand the reasons which may dictate normal or abnormal results in the metabolic NBS.
MATERIAL AND METHODS
Since 2004, the newborns are screened in Portugal for metabolic diseases, by tandem mass spectrometry.
Dried blood spots are collected between the 3rd and the 6th days of life and analyzed for amino acids and
Table 1 – Screened metabolic disorders with phenylalanine, 
tyrosine or methionine as primary markers
acylcarnitines (3). Phenylalanine, tyrosine and methionine are primary markers of four of the 24 metabolic diseases
screened (Table 1) and are among the analyzed amino acids. All samples presenting a combination of increased
Metabolic disease Primary markers
Phenylketonuria Phe (↑) and Tyr (↓)
values of phenylalanine plus tyrosine or methionine are selected for enzymatic total galactose determination using
Tyrosinemia Tyr (↑)
Classical Homocystinuria Met (↑)
the Neonatal Total Galactose Screening Assay from ZenTech. The cases with increased total galactose (N<5 mg/dL)
are considered suspect for galactosemia and are urgently reported to the reference metabolic treatment center
MAT I/III deficiency Met (↑)
closer to the newborn’ s residence, for clinical evaluation and diagnosis confirmation.
RESULTS
Since 2004, 1,016,168 newborns were screened for 24 metabolic disorders.
DISCUSSION
The Portuguese NBS program does not include CG screening. However,
During this time, 18 positive cases for CG come to our knowledge (Table 2), but only since the beginning of PKU screening in 1979 several cases have been identified
eight of these, shaded blue in Table 2, presented NBS results suggestive of CG. due to increased Phe levels and after 2004, with the expanded metabolic
screening, due to increased combined levels of Phe, Tyr and Met. The analysis
Case Age at Gal Tyr Phe Met
GALT gene
Table 2 – NBS and molecular results of patients with galactosemia
of NBS results of the 18 CG cases that come to our knowledge since 2004,
reveals that less than 50% of the cases presented abnormal results. We tried to
number screening (d) (N<5 mg/dL) (N<210 µM) (N<150 µM) (N<57 µM)
1 4 259 663 127 37 not available
2 1 50 1870 324 183 not available
correlate the abnormal results with the newborn’ age at screening, but doesn’t
seem to exist any correlation. We also tried to correlate these results with the
3 5 132 159 74 21 not available
4 5 248 914 123 41 not available
mutation present in the GALT gene, but we don’t have enough data.
5 not available 350 1072 332 57 not available
6 3 134 96 61 21 not available
7 10 23 101 40 27 not available
8 5 575 213 119 44 not available
9 2 183 163 88 32 not available
CONCLUSION
10 5 410 801 153 51 not available
11 4 280 266 164 41 not available
During this period, 2004-2017, 44% of GC cases were identified by NBS.
The possibility of a galactosemia diagnosis must always be considered for
12 6 456 965 471 46 p.Q188R/p.Q188R
13 4 66 555 181 55 p.Q188R/p.Q188R
newborns presenting compatible clinical signs, even in the presence of a normal
metabolic NBS result.
14 not available 121 735 301 71
IVS8 ds +13 A-G/ 
IVS8 ds +13 A-G
15 4 60 99 60 22
IVS2 as -2 A-G/ 
p.Y323C
16 3 127 558 138 56 p.Q188R/p.K285N
17 4 84 236 110 18 not available
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